Extended release bupivacaine formulations for postoperative analgesia: an update

被引：55

作者：

Balocco, Angela Lucia ^{[1
]}

Van Zundert, Pieter G. E. ^{[2
]}

Gan, Sophie S. ^{[3
]}

Gan, Tong J. ^{[4
]}

Hadzic, Admir ^{[1
]}

机构：

[1] ZOL, NYSORA, Genk, Belgium

[2] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands

[3] George Washington Univ, Washington, DC USA

[4] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA

来源：

CURRENT OPINION IN ANESTHESIOLOGY | 2018年 / 31卷 / 05期

关键词：

liposomal bupivacaine; multimodal analgesia; postoperative analgesia; TRANSVERSUS ABDOMINIS PLANE; LIPOSOMAL BUPIVACAINE; POSTSURGICAL ANALGESIA; PHARMACOKINETIC PROFILE; CONTROLLED-TRIAL; HERNIA REPAIR; PAIN-CONTROL; NERVE BLOCK; INFILTRATION; INJECTION;

D O I：

10.1097/ACO.0000000000000648

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Purpose of reviewNew formulations of local anesthetics with sustained release and longer duration of action are being developed to improve patient outcomes following surgery. This review summarizes the efficacy and safety of the three most recently developed extended-release formulations of the local anesthetic, bupivacaine.Recent findingsBupivacaine liposome injectable suspension (EXPAREL) encapsulates bupivacaine in biodegradable liposomes. It is currently the only extended-release formulation of bupivacaine approved by the FDA for infiltration of the tissues during surgery and for interscalene nerve block analgesia following shoulder surgery. SABER-Bupivacaine and HTX-011, are extended-release bupivacaine products in active development. Available data suggest relative safety and efficacy of all three formulations, although more data are needed to define their indications and dosing.SummaryExtended-release bupivacaine formulations are promising alternatives to prolong duration of analgesia. To date, only EXPAREL has been approved by the FDA for tissue infiltration during surgery and for interscalene nerve block.

引用

页码：636 / 642

页数：7

共 37 条

[1]

[Anonymous], 2018, FDA BRIEF FDA APPROV

[2]

Bergese Sergio D, 2012, J Pain Res, V5, P107, DOI 10.2147/JPR.S30861

[3]

Beverly Anair, 2017, Anesthesiol Clin, V35, pe115, DOI 10.1016/j.anclin.2017.01.018

[4]

Butterwoth J IV, 2017, Hadzic's textbook of regional anesthesia and acute pain management, V2nd, P124